Matinas BioPharma (MTNB)
XASE:MTNB
Top Page
Matinas BioPharma
(NYSE MKT:MTNB)
Select Model
Select Model
Rating:42Neutral
Price Target:
$0.52
▼(-19.38% Downside)
Action:ReiteratedDate:04/04/26
The score is held down primarily by weak financial fundamentals (zero revenue, ongoing losses and cash burn, and a much thinner equity base), reinforced by a persistent technical downtrend. A recent NYSE American compliance notice and going-concern language add meaningful risk, while valuation signals are limited by negative earnings and no dividend support.
Positive Factors
LNC drug-delivery platform
Matinas’s LNC lipid-delivery platform is a durable strategic asset: platform technologies can spawn multiple programs and partnerships, enabling leverage of R&D across indications. As a core capability in oral and lipid-based delivery, it supports longer-term competitive differentiation versus single-product peers.
Negative Factors
Pre-revenue business model
Zero revenue leaves the company dependent on successful clinical outcomes and external funding to reach commercialization. Lack of commercial cash flow reduces earnings visibility, increases financing frequency, and means long-term value hinges on binary clinical/regulatory milestones rather than recurring business metrics.
Read all positive and negative factors
Positive Factors
Negative Factors
LNC drug-delivery platform
Matinas’s LNC lipid-delivery platform is a durable strategic asset: platform technologies can spawn multiple programs and partnerships, enabling leverage of R&D across indications. As a core capability in oral and lipid-based delivery, it supports longer-term competitive differentiation versus single-product peers.
Read all positive factors
Matinas BioPharma (MTNB) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$3.50M
Dividend YieldN/A
Average Volume (3M)52.28K
Price to Earnings (P/E)―
Beta (1Y)1.86
Revenue GrowthN/A
EPS Growth25.19%
CountryUS
Employees3
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.03
Shares Outstanding6,406,191
10 Day Avg. Volume45,057
30 Day Avg. Volume52,280
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.66
Price to Sales (P/S)0.00
P/FCF Ratio-0.46
Enterprise Value/Market Cap0.11
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-0.06
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-5
Revenue Forecast (FY)$93.32M
Matinas BioPharma Business Overview & Revenue Model
Company Description
Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of various product candidates. It develops products using its lipid nanocrystal (LNC) platform technology. The company's LNC del...
How the Company Makes Money
null...
Matinas BioPharma Earnings Call Summary
Earnings Call Date:Aug 14, 2024
(Q2-2024)
| % Change Since: |
Next Earnings Date:May 07, 2026
Earnings Call Sentiment Neutral
The earnings call presented a mixed picture, with notable progress in MAT2203 licensing and financial management, counterbalanced by the lack of revenue, delays in trial timelines, and challenges in oncology trials. The sentiment is cautiously optimistic but acknowledges the hurdles that need addressing.Positive Updates
MAT2203 Licensing Progress
Matinas BioPharma has signed a nonbinding term sheet for the licensing of global rights to develop, manufacture, and commercialize MAT2203, indicating potential future growth and collaborations.
Negative Updates
No Revenue Reported
The company did not report any revenue for the second quarter of 2024, similar to the same period in 2023.
Read all updates
Q2-2024 Updates
Positive
Negative
MAT2203 Licensing Progress
Matinas BioPharma has signed a nonbinding term sheet for the licensing of global rights to develop, manufacture, and commercialize MAT2203, indicating potential future growth and collaborations.
Read all positive updates
Company Guidance
During the Matinas BioPharma Q2 2024 earnings call, several key metrics and guidance updates were provided. The company reported a net loss of $5.7 million or $0.02 per share for the quarter, a slight improvement from the $6.1 million or $0.03 per share loss in the same period of 2023. Total costs and expenses decreased to $5.8 million from $6.2 million year-over-year, primarily due to reduced clinical development and administrative costs. Matinas did not report any revenue for the quarter, consistent with the previous year. Cash, cash equivalents, and marketable securities stood at $14.3 million as of June 30, 2024, an increase from $13.8 million at the end of 2023, bolstered by $10 million in gross proceeds from a registered direct offering. The company is advancing plans for the ORALTO Phase III trial for MAT2203, with ongoing preparations and a potential start in the fourth quarter of 2024. Additionally, Matinas has signed a nonbinding term sheet for the global rights to develop, manufacture, and commercialize MAT2203, with the final agreement potentially including upfront payments, development and commercial milestones, and royalties.Matinas BioPharma Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
48
Neutral
Cash Flow
22
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 1.10M | 3.19M | 33.00K |
| Gross Profit | 0.00 | 0.00 | 1.10M | -13.49M | -14.55M |
| EBITDA | -6.96M | -19.19M | -22.82M | -24.23M | -24.45M |
| Net Income | -10.96M | -24.25M | -22.94M | -21.00M | -23.28M |
Balance Sheet | |||||
| Total Assets | 7.21M | 12.64M | 25.10M | 78.87M | 61.33M |
| Cash, Cash Equivalents and Short-Term Investments | 4.00M | 7.28M | 13.76M | 28.81M | 49.62M |
| Total Debt | 1.35M | 2.89M | 3.56M | 4.12M | 4.70M |
| Total Liabilities | 2.38M | 5.05M | 5.86M | 42.23M | 8.83M |
| Stockholders Equity | 4.83M | 7.59M | 19.25M | 36.64M | 52.49M |
Cash Flow | |||||
| Free Cash Flow | -7.01M | -15.88M | -15.50M | -20.05M | -15.48M |
| Operating Cash Flow | -7.01M | -15.88M | -15.28M | -19.16M | -15.22M |
| Investing Cash Flow | 335.00K | 9.21M | 13.24M | 4.88M | 16.77M |
| Financing Cash Flow | 3.39M | 9.17M | -7.00K | 79.00K | 6.96M |
Matinas BioPharma Technical Analysis
Negative
0.65
Price Trends
0.61
Negative
0.71
Negative
1.07
Negative
Market Momentum
-0.02
Positive
43.37
Neutral
30.48
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For MTNB, the sentiment is Negative. The current price of 0.65 is above the 20-day moving average (MA) of 0.60, above the 50-day MA of 0.61, and below the 200-day MA of 1.07, indicating a bearish trend. The MACD of -0.02 indicates Positive momentum. The RSI at 43.37 is Neutral, neither overbought nor oversold. The STOCH value of 30.48 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for MTNB.
Matinas BioPharma Risk Analysis
Matinas BioPharma disclosed 54 risk factors in its most recent earnings report. Matinas BioPharma reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Matinas BioPharma Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | $8.19M | -0.44 | -87.05% | ― | -62.75% | 23.87% | |
45 Neutral | $1.80M | -0.09 | 1121.04% | ― | -87.93% | 65.26% | |
44 Neutral | $6.78M | -0.34 | -253.43% | ― | ― | 94.52% | |
44 Neutral | $2.41M | -0.46 | -155.01% | ― | ― | 78.52% | |
42 Neutral | $3.50M | -0.29 | -157.24% | ― | ― | 25.19% |
* Healthcare Sector Average
MTNB
Matinas BioPharma
0.55
<0.01
1.11%
NCNA
Nucana
1.63
-148.37
-98.91%
ADIL
Adial Pharmaceuticals
1.69
-16.31
-90.61%
SILO
Silo Pharma
0.35
-0.68
-66.18%
APRE
Aprea Therapeutics
0.72
-0.88
-55.03%
HCWB
HCW Biologics
0.27
-8.61
-96.99%
Matinas BioPharma Corporate Events
Delistings and Listing ChangesFinancial DisclosuresRegulatory Filings and Compliance
Matinas BioPharma Faces NYSE American Listing Compliance Notice
Negative
Apr 3, 2026
On April 2, 2026, Matinas BioPharma received a notice from NYSE American that it is out of compliance with the exchange’s stockholders’ equity listing standards after posting losses in each of the five years through December 31, 2025, ...
Executive/Board ChangesRegulatory Filings and Compliance
Matinas BioPharma CEO Named Interim Chief Financial Officer
Neutral
Jan 23, 2026
On November 18, 2025, Matinas BioPharma Holdings, Inc. reported that its Chief Financial Officer, Keith Kucinski, would resign effective January 17, 2026, to pursue other opportunities, and on January 22, 2026, the board appointed Chairman, Presid...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.